Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

ELOQUENT-1 investigators

科研成果: 期刊稿件 › 文章 › 同行评审

32 引用 （Scopus）

指纹

探究 'Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial' 的科研主题。它们共同构成独一无二的指纹。

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases